Total Payments
$307,779
2024 Payments
$7,368
Companies
17
Transactions
210
Medicare Patients
2,625
Medicare Billing
$350,693
Payment Breakdown by Category
Other$152,354 (49.5%)
Consulting$91,962 (29.9%)
Travel$52,645 (17.1%)
Food & Beverage$5,864 (1.9%)
Research$4,775 (1.6%)
Education$89.99 (0.0%)
Gifts$89.76 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $152,354 | 52 | 49.5% |
| Consulting Fee | $91,962 | 13 | 29.9% |
| Travel and Lodging | $52,645 | 53 | 17.1% |
| Food and Beverage | $5,864 | 78 | 1.9% |
| Unspecified | $4,775 | 12 | 1.6% |
| Education | $89.99 | 1 | 0.0% |
| Gift | $89.76 | 1 | 0.0% |
Payments by Type
General
$303,004
198 transactions
Research
$4,775
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $85,843 | 69 | $0 (2024) |
| Astellas Pharma Global Development | $62,644 | 27 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $46,330 | 32 | $0 (2019) |
| Astellas Pharma US Inc | $35,376 | 13 | $0 (2021) |
| Astellas Pharma Inc | $31,704 | 22 | $0 (2019) |
| PFIZER INC. | $16,322 | 20 | $0 (2024) |
| Myovant Sciences Inc. | $13,147 | 7 | $0 (2022) |
| GENZYME CORPORATION | $12,273 | 4 | $0 (2017) |
| Progenics Pharmaceuticals, Inc. | $1,625 | 1 | $0 (2022) |
| Incyte Corporation | $1,565 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,368 | 13 | Janssen Biotech, Inc. ($6,047) |
| 2023 | $3,476 | 8 | PFIZER INC. ($2,100) |
| 2022 | $22,371 | 18 | Janssen Biotech, Inc. ($14,422) |
| 2021 | $41,653 | 16 | Astellas Pharma US Inc ($26,280) |
| 2020 | $28,775 | 23 | Janssen Biotech, Inc. ($27,061) |
| 2019 | $83,560 | 54 | Astellas Pharma Inc ($31,704) |
| 2018 | $75,736 | 47 | Janssen Scientific Affairs, LLC ($31,781) |
| 2017 | $44,840 | 31 | GENZYME CORPORATION ($12,273) |
All Payment Transactions
210 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/10/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/21/2024 | 180 Medical, Inc. | GENTLECATH GLIDE (Device) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: CONTINENCE CARE | ||||||
| 07/25/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $33.70 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/07/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 03/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | Cash or cash equivalent | $65.93 | General |
| Category: Oncology | ||||||
| 03/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | Cash or cash equivalent | $11.75 | General |
| Category: Oncology | ||||||
| 03/15/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $652.50 | General |
| Category: Oncology | ||||||
| 03/14/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $109.96 | General |
| Category: Oncology | ||||||
| 03/12/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $260.33 | General |
| Category: Oncology | ||||||
| 02/27/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 02/23/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $416.70 | General |
| Category: Oncology | ||||||
| 01/17/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $399.29 | General |
| Category: Oncology | ||||||
| 12/02/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $111.35 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX | Food and Beverage | In-kind items and services | $107.45 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 04/18/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 03/17/2023 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,750.00 | General |
| Category: ONCOLOGY | ||||||
| 03/11/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX | Food and Beverage | In-kind items and services | $131.50 | General |
| Category: ONCOLOGY | ||||||
| 02/16/2023 | Janssen Research & Development, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $138.00 | General |
| Category: Oncology | ||||||
| 02/16/2023 | Janssen Research & Development, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $138.00 | General |
| Category: Oncology | ||||||
| 07/01/2022 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2022 | Myovant Sciences Inc. | ORGOVYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $790.00 | General |
| Category: HORMONE THERAPY | ||||||
| 06/21/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 06/08/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Travel and Lodging | In-kind items and services | $337.75 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer CRPC trials | Astellas Pharma Global Development | $1,699 | 3 |
| XTANDI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| PROSPER A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Astellas Pharma Global Development | $1,133 | 4 |
| Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-resistant Prostate Cancer: An Analysis of the PREVAIL Randomized Clinical Trial | Astellas Pharma Global Development | $492.45 | 2 |
| An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants | Astellas Pharma Global Development | $180.90 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 533 | 588 | $452,798 | $59,438 |
| 2022 | 12 | 737 | 845 | $600,786 | $90,711 |
| 2021 | 16 | 681 | 785 | $588,475 | $91,951 |
| 2020 | 15 | 674 | 801 | $600,100 | $108,593 |
Total Patients
2,625
Total Services
3,019
Medicare Billing
$350,693
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 55866 | Surgical removal of prostate and surrounding lymph nodes using an endoscope | Facility | 2023 | 19 | 19 | $116,780 | $18,147 | 15.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 156 | 177 | $62,658 | $7,884 | 12.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 80 | 83 | $41,666 | $5,560 | 13.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 57 | 57 | $36,822 | $5,431 | 14.7% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 83 | 99 | $87,021 | $5,364 | 6.2% |
| 38571 | Removal of lymph nodes of both sides of pelvis using an endoscope | Facility | 2023 | 12 | 12 | $34,668 | $3,276 | 9.5% |
| 52235 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | Facility | 2023 | 12 | 13 | $13,832 | $2,997 | 21.7% |
| 52234 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | Facility | 2023 | 14 | 16 | $15,760 | $2,926 | 18.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 25 | 26 | $18,174 | $2,873 | 15.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 37 | 37 | $16,058 | $2,109 | 13.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 23 | $5,953 | $1,320 | 22.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 11 | 11 | $1,771 | $858.89 | 48.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 14 | 15 | $1,635 | $693.10 | 42.4% |
| 55866 | Surgical removal of prostate and surrounding lymph nodes using an endoscope | Facility | 2022 | 29 | 29 | $160,705 | $34,105 | 21.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 207 | 249 | $85,443 | $11,584 | 13.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 94 | 94 | $59,174 | $9,556 | 16.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 100 | 113 | $55,142 | $8,346 | 15.1% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 101 | 138 | $114,182 | $7,868 | 6.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 86 | 86 | $36,001 | $4,958 | 13.8% |
| 38571 | Removal of lymph nodes of both sides of pelvis using an endoscope | Facility | 2022 | 16 | 16 | $40,756 | $4,360 | 10.7% |
| 52234 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | Facility | 2022 | 15 | 19 | $17,846 | $3,790 | 21.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 24 | 27 | $18,533 | $3,172 | 17.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 25 | 29 | $3,061 | $1,384 | 45.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 16 | $3,728 | $933.90 | 25.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 29 | 29 | $6,215 | $654.72 | 10.5% |
About Dr. Christopher Evans, M.D
Dr. Christopher Evans, M.D is a Urology healthcare provider based in Reno, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1356326060.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Evans, M.D has received a total of $307,779 in payments from pharmaceutical and medical device companies, with $7,368 received in 2024. These payments were reported across 210 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($152,354).
As a Medicare-enrolled provider, Evans has provided services to 2,625 Medicare beneficiaries, totaling 3,019 services with total Medicare billing of $350,693. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Reno, NV
- Active Since 12/14/2005
- Last Updated 04/26/2024
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1356326060
Products in Payments
- XTANDI (Drug) $90,267
- Erleada (Drug) $70,531
- ERLEADA (Drug) $51,407
- Xtandi (Drug) $25,706
- ENZALUTAMIDE (Drug) $23,271
- JEVTANA (Drug) $12,273
- ORGOVYX (Drug) $11,567
- TALZENNA (Drug) $6,750
- DARZALEX (Biological) $3,023
- PYLARIFY (Drug) $1,625
- ZYTIGA (Drug) $625.96
- NO PRODUCT DISCUSSED (Drug) $279.45
- Da Vinci Surgical System (Device) $89.76
- Enzalutamide (Drug) $50.95
- DOPTELET (Drug) $33.70
- NEOX (Medical Supply) $23.43
- GENTLECATH GLIDE (Device) $17.60
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Reno
Nicholas Hauser, M.d, M.D
Urology — Payments: $88,828
Urology $88,828
Dr. Eric Kim, Md, MD
Urology — Payments: $25,453
Urology $25,453
Dr. Angelo Kanellos, M.d, M.D
Urology — Payments: $15,866
Urology $15,866
Ross Anderson
Urology — Payments: $6,277
Urology $6,277
Timothy Suttle, M.d, M.D
Urology — Payments: $4,864
Urology $4,864
Matthew Mccormack, M.d, M.D
Urology — Payments: $4,341
Urology $4,341